19 results about "Antibody titer" patented technology

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The application discloses a water-in-oil-in-water adjuvant composition and a preparation method and application thereof, and belongs to the technical field of biological pharmacy. The adjuvant composition is composed of squalene, Tween-80, Span 85 and physiological saline or a phosphate buffer, wherein the volume percentage of squalene is 1% to 6%, the volume percentage of Tween-80 is 0.5% to 3%, the volume percentage of Span 85 is 0.5% to 3%, and the rest is solvent. The composition is prepared into uniform multiple emulsions with a particle size of 40 to 220 nm through high-speed shearing and high-pressure homogenization. The adjuvant can significantly enhance the humoral immune response of various vaccines, and the antibody titer is increased by 4 to 16 times compared with traditional aluminum adjuvant, meanwhile, the adjuvant has low local irritation and good safety, can be stored for more than 24 months at 2 to 8 DEG C, and is suitable for large-scale production.

The application discloses a phosphoric acid modified protein or polypeptide, a preparation method thereof and application thereof in vaccines, and belongs to the field of protein phosphoric acid modification. The preparation method of the phosphoric acid modified protein or polypeptide is as follows: a compound containing an aldehyde group and a phosphate group is subjected to nucleophilic reaction with a protein or polypeptide to form a Schiff base; a reducing agent is used to reduce the Schiff base, and after post-treatment, the phosphoric acid modified protein or polypeptide is obtained. After the phosphoric acid modified protein product prepared by the method is prepared into a vaccine with an aluminum hydroxide adjuvant and mice are immunized, the antibody titer is significantly increased. This is of great significance for increasing the immune effect, reducing the inoculation dose, saving the antigen amount and improving the immune response of some people or in specific conditions.

Provided are compositions and methods for reducing pre-existing antibodies against viral vector or gene-editing related proteins. The compositions showed reduction in various antibody titers by administration of a liposome composition complexed with a protein or fragment thereof of a viral vector. The liposomes comprise phosphatidylcholine and phosphatidylserine, wherein some or all of the PS is present as lyso-PS. The compositions and methods can be used in conjunction with gene therapy and nucleic acid based vector based vaccinations and therapeutics.

This invention provides a method for detecting AAV antibody titers, belonging to the field of biomedical technology, comprising: S1 preparing serum-free AAV vectors with different MOI values; preparing a mixture containing different volumes of test serum samples and AAV vectors with known MOI values ​​for co-incubation; S2: adding plasmids containing the CRISPR-Cas9 gene editing system to electroporation buffer, performing electroporation on a known number of cells, adding the serum-free AAV vectors and mixture from step S1 to the electroporated cells respectively, and detecting the expression efficiency of the reporter gene after electroporation; S3: calculating the AAV antibody titer in the test serum sample based on the detection results. The main advantage of this invention is that it can display AAV antibody titers digitally and quantitatively, facilitating understanding and communication, and obtaining stable and reliable results using different cell lines and different AAV transduction doses. This method is easy to standardize and validate, saving time, effort, and detection costs compared to traditional methods, and directly reflects antibody neutralizing activity.

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h

This invention relates to the field of biomedical technology, providing a rabbit hemorrhagic disease virus (RHDV) type 2 fusion antigen protein and its applications. The fusion antigen protein comprises the RHDV2 VP60 protein sequence and an immunomodulatory CRM197 protein functional fragment, fused together via a linker peptide, and expressed and purified in an insect cell expression system. This invention improves the immunogenicity of the antigen protein by fusing the major capsid protein VP60 of RHDV2 with the immunomodulatory fragment of CRM197. Rabbit immunization experiments verified that the fusion antigen protein can induce high-titer specific antibodies, with serum antibody titers reaching 1:12800 and above, demonstrating good immunization effects. The fusion antigen protein of this invention can be used to prepare a vaccine for the prevention of RHDV2 infection, providing a new technical solution for the prevention and control of RHDV2 disease.

To provide an oral health support method that allows even ordinary users to easily and efficiently predict their risk of future tooth loss, and to provide a system that utilizes information on the risk of future tooth loss to easily and efficiently support the oral health of users. [Solution] A method for supporting oral health, characterized by predicting the risk of tooth loss using antibody titer test results related to oral bacteria and oral quantity test results, and An oral health support system in which a computer predicts the risk of tooth loss from the results of an antibody titer test related to oral bacteria and the results of an oral bacteria quantity test of the user, using a predetermined classification with variables being antibody titers related to oral bacteria and the amount of oral bacteria in the oral cavity. The system then creates information useful for maintaining and promoting oral health, including the predicted risk of tooth loss, and provides it to the user, medical institution, or healthcare professional.

This invention discloses a chimeric peptide cFel d1-4 based on T-cell antigenic epitopes of feline allergen proteins Fel d1 and Fel d4, its encoding nucleic acid, and its applications, relating to the field of molecular biology. This invention provides a chimeric peptide cFel d1-4, comprising the region represented by amino acid residues 26-41, 46-59, 85-98, 132-140, and 146-153 of the feline allergen Fel d1 antigen, and the region represented by amino acid residues 1-12, 36-48, 83-94, 114-130, and 160-168 of Fel d4. Experiments of this invention demonstrate that the chimeric peptide cFel d1-4 immunizes animals and yields high antibody titers, simultaneously reducing the levels of both feline allergens Fel d1 and Fel d4 proteins.

This invention discloses a serogroup B meningococcal vaccine and its application. The serogroup B meningococcal vaccine contains one or more recombinant proteins with amino acid sequences as shown in SEQ ID NO:1-7. The vaccine against serogroup B meningococcus of this invention induces a strong humoral immune response and broad-spectrum protective efficacy. Compared with existing technologies, the vaccine against serogroup B meningococcus of this invention has high antibody titers and broad protective efficacy. It has broad application value and positive social benefits in preventing diseases caused by serogroup B meningococcus infection and alleviating severe cases.

This invention discloses a sodium caseinate-based Pickering emulsion, its preparation method, and its application, belonging to the field of vaccine adjuvant technology. This invention is the first to propose using Salmonella Typhimurium flagellin and sodium caseinate as raw materials to formulate a Pickering emulsion. The prepared Pickering emulsion has the characteristics of small particle size, good biocompatibility, and high stability, and can induce a high immune response in the body. This invention is also the first to propose the application of the Pickering emulsion formulated using Salmonella Typhimurium flagellin and sodium caseinate as raw materials as a vaccine adjuvant. The Pickering emulsion prepared by this invention has a simple preparation process, requiring only mixing and homogenization, and can effectively load the model antigen OVA. This emulsion has good cellular safety and can promote the endocytosis of exogenous antigens by macrophages. The emulsion can induce the body to produce high levels of antibody titers, with antibody titers reaching more than 120,000 times.

This application discloses a composition for combating necrotizing enteritis in chickens and its application. The active ingredients in the composition, by weight, consist of 5 parts paeonol, 5 parts farnesol, and 1 part soy saponin. This composition can also be formulated into oral liquids, tablets, granules, or powders using paeonol, farnesol, and soy saponin as active ingredients and excipients, with a dosage of 100-1000 mg / kg body weight; or the composition can be directly added to feed at a dosage of 0.1%-1% of the total weight of the chicken feed. The composition formed by paeonol, farnesol, and soy saponin provided in this application, as a drug, has high safety and no toxic side effects. It can effectively inhibit the proliferation of chicken-derived pathogens such as Clostridium perfringens, Salmonella, and Escherichia coli, effectively increase the antibody titer of Newcastle disease vaccine, and alleviate the reduction in chicken production performance, the increase in pro-inflammatory cytokines, and the impairment of intestinal absorption and barrier function caused by coccidiosis and necrotizing enteritis.

The application discloses a chikungunya fever nucleic acid vaccine and belongs to the technical field of nucleic acid vaccines. A transmembrane protein sequence is obtained through multiple recombination optimizations, the protein sequence is connected with E2 and E1 protein sequences, a polyprotein is constructed, and the E2 and E1 proteins of chikungunya fever can be efficiently expressed through codon optimization and circular mRNA or linear mRNA technology. Compared with original virus protein sequences, the expression efficiency is improved by 2.7 times, the antibody titer of a mouse immunized by the circular mRNA vaccine is improved by 4.7 times, and the antibody duration is longer.

The application provides a fluorescent image intelligent recognition method, system, device and medium, and relates to the technical field of image recognition. The method comprises the following steps: acquiring a plurality of original fluorescent images corresponding to a plurality of dilutions of a sample; extracting texture morphological features, fluorescent bright spot spatial distribution features and average fluorescent intensity of a cell nucleus region in a target original fluorescent image, the target original fluorescent image being any one of the plurality of original fluorescent images; fusing the texture morphological features and the fluorescent bright spot spatial distribution features to obtain a mixed feature vector; judging the mixed feature vector through a preset karyotype classification model to obtain a karyotype category of the target original fluorescent image; and calculating an antibody titer value according to the plurality of dilutions, the karyotype category corresponding to each dilution and the average fluorescent intensity corresponding to each dilution. The technical solution provided by the application improves the efficiency, objectivity and accuracy of detection.

This invention relates to the field of veterinary drug product technology, and more specifically, to a veterinary vaccine enhancer and its preparation and application. The veterinary vaccine enhancer comprises, by weight, the following components: 20-30 parts bacterial polysaccharide, 20-30 parts astragalus polysaccharide, 10-20 parts saponin, 4-12 parts vitamin B and C compound additive, and 1-5 parts polyethylene glycol 1000. The vaccine prepared using this invention is stable, safe, has high antibody titers, rapid antibody production, and long-lasting immunity, exhibiting excellent overall performance. The preparation method of the veterinary vaccine enhancer of this invention is simple, convenient, and low-cost, suitable for large-scale production and widespread application.

The application discloses an influenza virus subunit vaccine and a preparation method thereof, and relates to the field of biological medicines. Each dose contains H1N1, H3N2 and Victoria; the influenza virus subunit vaccine is prepared through virus inoculation, proliferation culture, allantoic fluid harvesting, clarification, inactivation, ultrafiltration concentration, lysis purification, mixing, sterilization filtration and subpackaging. The application significantly enhances the dendritic cell targeted uptake and rapid release of antigens through the design of mannose modified small liposomes and pH responsive channels; in combination with the precise controlled release of the graded lysis micelles, the antibody titer and immunological persistence are obviously improved, the single dose protection period is longer, and the defects of the traditional trivalent vaccine in the insufficient immunological intensity are effectively made up.

This invention belongs to the field of goat vaccine technology and is an application of a vaccine for the prevention of small ruminant plague (PPR) and sheep pox. This PPR-sheep pox vaccine is an improvement on the injection method of a bivalent live PPR-sheep pox vaccine, suitable for doubling the intramuscular injection in goats. Each injection of 1 ml of the bivalent live PPR-sheep pox vaccine results in a population antibody titer of 70% for both PPR and sheep pox after 30 days, and sheep pox antibody titer can still be detected after 180 days. This PPR-sheep pox vaccine demonstrates good safety and PPR immunity protection in Alashan white cashmere goats. Furthermore, the vaccine is suitable for intramuscular injection, which meets the needs of sheep pox immunization and control, and is suitable for practical grassroots disease prevention operations. It provides important technical support for the scientific prevention and control of diseases in regional white cashmere goats. Promoting the use of this PPR-sheep pox vaccine can prevent both PPR and sheep pox.

The application discloses an antigen-containing composition and application thereof. The composition contains an antigen selected from staphylococcus aureus antigens and an adjuvant selected from one or more of aluminum adjuvants, MF59 adjuvants, saponin adjuvants, CpG ODN adjuvants and MPL adjuvants. The nano-vaccine composition against staphylococcus aureus of the application can induce a very strong humoral immune response and higher protection efficacy. Compared with the prior art, the nano-vaccine composition against staphylococcus aureus of the application has high antibody titer and good protection efficacy.